...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Kidney International Reports >Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
【24h】

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle

机译：缺氧诱导的因子 - 脯氨酰羟化酶抑制剂，用于治疗CKD中的贫血：额外的拼图拼图

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The treatment of anemia in pa- tients with chronic kidney disease(CKD)remainschallenging3 decades after the regulatory approval of recombinant human erythropoietin in 1989 and the subsequent approval of its de- rivatives, collectively known as erythropoiesis-stimulating agents (ESAs). In 2018, only 14.6% of pa- tients in the United States were receiving ESAs at the time of end- stage kidney disease onset despite a mean Hb level in this population of 9.3 g/dl. 1 ESA hyporesponsive- ness, the failure to achieve target Hb level despite escalating doses of ESA, is associated with adverse clinical outcomes and is an unmet need for anemia treatment in the CKD population, particularly among those receiving HD in whom it is best described. The confluence of barriers to effective.
机译：1989年重组人促红细胞生成素的调控患者慢性肾病（CKD）贫血患者的贫血患者治疗患者的患者，随后批准其参数，统称为促红细胞兴奋剂（ESA）。 2018年，尽管该人群为9.3克/ DL的平均HB水平，但美国只有14.6％的肾脏疾病发病时接受欧洲疗养院。 1 ESA低估，虽然升级为ESA剂量升级，但仍有目标HB水平，与不良临床结果有关，并且是对CKD人群中贫血治疗的未满足需求，特别是在其最佳描述的那些中的那些HD中。 障碍有效的汇合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号